Wall Street analysts forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will report sales of $10.10 million for the current quarter, Zacks reports. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with estimates ranging from $9.30 million to $11.00 million. The company is scheduled to issue its next earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year sales of $33.23 million for the current year, with estimates ranging from $31.23 million to $36.12 million. For the next fiscal year, analysts forecast that the firm will report sales of $95.31 million per share, with estimates ranging from $75.00 million to $116.70 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.15. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. The business had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.84 million.

Several research analysts have recently commented on ADMS shares. BidaskClub upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, May 1st. HC Wainwright set a $45.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 6th. Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th. Mizuho restated a “buy” rating and issued a $75.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday. Finally, Piper Jaffray Companies set a $49.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, April 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $45.00.

NASDAQ ADMS opened at $22.43 on Friday. Adamas Pharmaceuticals has a 52 week low of $13.85 and a 52 week high of $44.00. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.74 and a current ratio of 9.92. The firm has a market cap of $628.10 million, a PE ratio of -5.65 and a beta of 1.42.

In related news, COO Richard King sold 2,501 shares of the business’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $25.48, for a total value of $63,725.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jennifer J. Rhodes sold 1,002 shares of the business’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $25.48, for a total transaction of $25,530.96. The disclosure for this sale can be found here. 24.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new stake in Adamas Pharmaceuticals during the second quarter worth about $130,000. Sei Investments Co. increased its stake in Adamas Pharmaceuticals by 49.8% during the first quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 2,536 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Adamas Pharmaceuticals by 43.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock worth $196,000 after purchasing an additional 2,293 shares during the period. State Board of Administration of Florida Retirement System purchased a new stake in Adamas Pharmaceuticals during the second quarter worth about $203,000. Finally, GSA Capital Partners LLP purchased a new stake in Adamas Pharmaceuticals during the second quarter worth about $212,000. Hedge funds and other institutional investors own 92.32% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Read More: Earnings Per Share

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.